Compare Honest Company Inc (HNST) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honest Company Inc vs Sana Biotechnology Inc — how do they compare? Honest Company Inc trades at $3.89 (market cap $426.55M), while Sana Biotechnology Inc trades at $3.2 (market cap $873.84M). The key difference: Sana Biotechnology Inc is far larger — about 2× Honest Company Inc's market cap, and Honest Company Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| HNST | SANA | |
|---|---|---|
Market Cap | $426.55M | $873.84M |
Sector | Consumer Staples | Health |
52-Week High | $4.95 | $5.92 |
52-Week Low | $2.10 | $2.68 |
Enterprise Value | $347.95M | $848.03M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HNST trades at $3.87, up 1.04% today, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.01, meeting estimates, but has missed expectations in two of the last three quarters. Revenue declined to $371.32 million in 2025 from $378 million in 2024, with a net loss of $15.69 million. Positive cash flow from operations of $15.12 million and record gross margins near 34% highlight operational improvements amid challenges.
The outlook remains mixed; analyst consensus is cautious with 30% buy ratings. Upside potential exists from gross margin expansion and cost controls, but risks include persistent net losses, competitive pressures in personal care, and reliance on retail channel growth. Investor sentiment is neutral, pending sustained profitability and revenue stabilization in 2026.
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
